NCT03008369View on ClinicalTrials.gov

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

December 1, 2020

Study Completion Date

September 28, 2022

Conditions
Malignant Adrenal Gland PheochromocytomaMalignant ParagangliomaMetastatic Adrenal Gland Pheochromocytoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenvatinib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER